Simcere’s Cancer Drug Endostar Passes Phase IV Test

Simcere Pharmaceutical Group (先声药业) has completed a Phase IV clinical trial of Endostar, its patented cancer drug. Endostar, a Class-1 drug with an anti-angiogenesis mechanism, was approved by the SFDA in 2005 to treat non-small cell lung cancer (NSCLC). Simcere said the drug, which was administered as an adjunct to chemotherapy, “significantly” improved outcomes without causing additional adverse effects. More details... Stock Symbol: (NYSE: SCR)